About RSNN

A variety of activities support our mission. These include a yearly RSNN workshop around a topic that deserves or attracts interest, and also scientific sessions during conferences such as FIGON Dutch Medicines Days. Alongside its meeting reports, the RSNN stimulates publication of relevant papers based on RSNN activities designed to stimulate national and international debate on regulatory science. Participants in the network receive news on developments in the field via our regular newsletters.

The RSNN is an inclusive organization, with all activities open to anyone interested. Such inclusiveness helps us to set agendas for future research, and to act as a breeding ground for new research initiatives.

Legacy

The RSNN was founded on October 5, 2015, during the FIGON Dutch Medicines Days. The initiative was started by the Medicines Evaluation Board (MEB); the TI Pharma Escher project; and the Dutch Society of Pharmaceutical Medicine. The goal was to consolidate and strengthen national research networks in the field of regulatory science.   

Until 2017, the RSNN was funded by the MEB with independent grants from Pfizer and Janssen, and governed by a Steering Committee with the support of an Advisory Board. In 2018, a partnership was formed by the MEB; the Association of Innovative Medicines (VIG); Utrecht University (UU); University Medical Center Groningen (UMCG); and Lygature, in order to further strengthen and expand the network. The RSNN is co-financed by the MEB, the Association of Innovative Medicines (VIG) and HollandBIO.

Steering Committee

The RSNN Steering Committee consists of two representatives from academia, two representatives from governmental bodies, and two representatives from industry. It is chaired by professor Bert Leufkens (Utrecht University). Members of the Steering Committee are as follows:

Advisory Board

Members of the RSNN Advisory Board support the Steering Committee. They provide input to the organization for RSNN events, policy plans, project output, and future topics. Members of the Advisory Board are as follows:

• Francisco Hernandez, AstraZeneca, Chair
• Dr. Peter Bertens, Vereniging Innovatieve Geneesmiddelen (VIG)
• Prof. Dr. Michaël Boele van Hensbroek, Centrale Commissie Mensgebonden Onderzoek (CCMO)
• Mike Broeders, FAST
• Layla Fitoury, Sanofi
• Dr. Helga Gardarsdottir, Utrecht University
• Prof. Dr. Joop van Gerven, Amsterdam UMC
• Marianne Groeneveld, Pfizer
• Dr. Jarno Hoekman, Utrecht University
• Tinka Hogeling, Gilead
• Carla Hollak, Amsterdam UMC
• Eline Hoogstra, patient representative
• Dr. Florence van Hunsel, Lareb
• Gideon van den Kieboom, Bayer
• Eugenie van Lieshout, Johnsson&Johnsson
• Peter van Meer, Medicines Evaluation Board (CBG-MEB)
• Stephan Meijer, patient representative
• Peter Mol, UMCG/Medicines Evaluation Board (CBG-MEB)
• Chantal van Litsenburg, Leiden Universitair Medisch Centrum (LUMC)
• Connie van Oers, UniQure/RegNed
• Patricia Otto-Terlouw, Medicines Evaluation Board (CBG-MEB)
• Bart Scheerder, Dutch Clinical Research Foundation (DCRF)
• Lonneke Timmers, Zorginstituut Nederland (ZIN)
• Carolien van de Wal, MSD

Program Office

The RSNN Program Office at Lygature handles the coordination, program management and communications. In addition, Lygature is responsible for the scientific management and stakeholder management.